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DFT calculationAbstract Gold (III)-N,N-dimethyldithiocarbamate [DMDT(Au)X2] complexes have recently
gained increasing attention as potential anticancer agents because of their strong tumor cell
growth–inhibitory effects, generally achieved by exploiting non-cisplatin-like mechanisms of action.
The goal of our research work is to encapsulate the gold(III) dimethyldithiocarbamate complexes as
anticancer with cucurbit[n]urils (CB[n= 5, 6]) by accurate calculations, to predict the inclusion
complex formation of gold(III) species with cucurbiturils (CB[n= 5, 6]). The calculations were car-
ried out just for the 1:1 stoichiometric complexes. Upon encapsulation, binding energy, thermody-
namic parameters, structural parameters and electronic structures of complexes are investigated.
The results of the thermodynamic calculations and the binding energy show that the inclusion pro-
cess is exothermic and the CB[6]/[DMDT(Au)Br2] complex is more stable than other complexes.
The ﬁnal geometry of CB[n]/drugs indicates that the drugs were expelled from the cavity of
CB[n]. NBO calculations reveal that the hydrogen bonding between CB[n] and drugs and electro-
static interactions are the major factors contributing to the overall stabilities of the complexes.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Since the introduction of Pt(II)-based ﬁrst anticancer agents,
metal complexes and organometallic compounds have been
gaining growing importance in cancer therapy. The impressive
clinical effectiveness of cisplatin is limited by signiﬁcant side ef-
fects and by acquired or intrinsic resistance to the treatment
(Kelland, 2007). Thus, classic and unconventional Pt(II) and
Pt(IV) complexes have been introduced in therapy or are pres-
ently in advanced clinical trials. Moreover, innovative non-
platinum metal-based antitumor agents, whose activity do
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Figure 1 Gold(III) complexes with Au–S bonds (a) [DMDT(Au)Cl2], (b) [DMDT(Au) Br2], (c) [ESDT(Au)Cl2] and (d) [ESDT(Au)Br2].
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enzymes, have been developed (Alama1 et al., 2009). Of the
non-platinum metal compounds with antitumor activity, par-
ticular interest has been focused on gold and tin derivatives,
which have a common activity on mitochondria and a strong
afﬁnity to thiol groups of proteins and enzymes (Louie and
Meade, 1999; Robertson and Orrenius, 2002).
Based on their structural and electronic similarity to cis-
platin and cisplatin-related antitumor drugs gold(III) species
represent a promising class of potential anticancer agents.
However, the development of gold(III) complexes as therapeu-
tic drugs has been hampered by their low stability under phys-
iological conditions which remains a critical parameter in the
drug development of these species. Gold(III) complexes with
various ligands have been prepared and biologically investi-
gated (Gabbiani et al., 2007; Marzano et al., 2011). Most of
them are complexes with Au–N bonds (eventually containing
additional Au–O and Au–Cl bonds) but also some species with
Au–S or Au–C bonds and their bioactivities have been de-
scribed (Ott, 2009). Gold(III) complexes (see Fig. 1 for some
relevant examples) exhibited superior cytotoxic effects to
cisplatin, being also active in resistant cells and induced
apoptosis (Giovagnini et al., 2005; Ronconi et al., 2005). The
compounds showed good stability under physiological condi-
tions, bind readily to the DNA, inhibit both DNA and RNA
synthesis and induce fast DNA lesions. Experiments on red
blood cells indicated that hemolytic properties might contrib-
ute signiﬁcantly to the bioactivity of the agents (Ronconi
et al., 2006).Figure 2 General structures of cucurbit[n]urils.Cucurbit[n]urils (CB[n]), a family of pumpkin-like molecular
containers, are cyclic methylene-bridged glycoluril oligomers
with two portals lined by ureido carbonyl groups (Fig. 2) that
provide entry to their hydrophobic cavity (Lei et al., 2010).
While Cucurbit[6]uril (CB[6]) was ﬁrst discovered in 1905
(Behrend et al., 1905) and its macrocyclic structure was not
determined until 1981 in 2000, CB[6] was the one of the only
cucurbit[n]uril to receive any attention as a molecule useful in
the host–guest chemistry (Freeman et al., 1981). This changed
upon the discovery of different sized cucurbit[n]urils: CB[5],
CB[7], CB[8] and the isolation of free CB[10] (Kim et al.,
2000; Liu et al., 2005). Their discovery has led to a rapid in-
crease in the interest in the use of, CB[n] in a variety of ﬁelds
including: nano machines, chromatography, and drug delivery
(Wyman and Macartney, 2010).
There has been an increasing interest recently in using
cyclodextrins and cucurbit[n]urils to aid in the delivery of mol-
ecules of biological and medicinal interest, through host–guest
formation (Bali et al., 2006; Lagona et al., 2005; Faustino
et al., 2011; Sancho et al., 2011). Cucurbit[n]urils can encapsu-
late a variety of molecules within their hydrophobic cavity,
with the binding potentially further stabilized by favorable
electrostatic and hydrogen bonding interactions with the car-
bonyl rimmed portals (Bali et al., 2006). Encapsulation of
drugs inside a cucurbit[n]uril provides two beneﬁts. Protects
the drugs from degradation and increases the speciﬁcity of
the drugs, and uptake into cancerous cells. Consequently,
encapsulation in cucurbit[n]uril would protect the metal com-
plexes such as platinum complex from reactions with plasma
proteins in the bloodstream, but would not affect the reaction
of the metal complex with DNA inside the cell (Bali et al.,
2006). There has been increasing interest recently in using
cucurbit[n]urils to aid in the delivery of molecules of biological
and medicinal interest, through host–guest formation. Cucur-
bit[7]uril and cucurbit[8]uril molecules have been used to form
host–guest complexes with mononuclear, dinuclear and trinu-
clear platinum(II) complexes (Wheate et al., 2004; Wheate,
2008; Wang and Macartney, 2008; Anconi et al., 2011). There
are many reports on the theoretical studies of CB[n] (Marquez
et al., 2004; Pichierri, 2006; Buschmann et al., 2006; Bakovets
et al., 2008; Suvitha et al., 2010). Kim and coworkers have
shown that the inclusion complex formation of oxaliplatin
with cucurbit[7]uril has moderate cytotoxicity with a larger de-
crease in reactivity toward guanosine and L-methionine,
respectively (Jeon et al., 2005). Gejji and coworkers, made an
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ferrocene (Pinjari and Gejji, 2008).
Density functional theory has been successful in rationaliz-
ing popular concepts such as chemical reactivity and selectivity
of molecules based on their global and local reactivity indices.
The global index includes electronegativity (v) (Sen and Jor-
gensen, 1987) and hardness (g) (Sen and Jorgensen, 1987; Pear-
son, 1997), while the local index includes the Fukui function
(f(r) and (s(r)) (Yang and Parr, 1985). As we already know,
electronegativity may be considered as the power of an atom
in a given molecule to attract electrons to itself (Parr and
Yang, 1984). The idea of hardness was given by Pearson in
the context of the hard–soft-acid–base (HSAB) (Pearson,
1973) principle, which states that ‘‘hard likes hard and soft
likes soft’’. Another hardness-based principle is the maximum
hardness principle (MHP) (Pearson, 1993), which states that
‘‘it seems to be a rule of nature that molecules arrange them-
selves so as to be as hard as possible’’ (Pearson, 1987). For a
N-electron system with potential to act on an electron at r
due to the nuclear attraction plus such other external forces
as may be present external potential v(r) and total energy E,
electronegativity (v) (Sen and Jorgensen, 1987) and hardness
(g) (Pearson, 1993) are deﬁned as the following ﬁrst-order
(Pearson et al., 1978) and second-order (Parr and Pearson,
1983) derivatives, respectively:(a)
(b)
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where l is the electronic chemical potential, deﬁned as the neg-
ative of electronegativity. In addition, the global softness, S, of
the equilibrium state of an electronic system at temperature T,
is deﬁned as (Parr and Yang, 1989):
S ¼ 1
2g
¼ @N
@l
 
mðrÞ;T
ð3Þ
Recently, Parr and co-workers (Pearson et al., 1999) have
introduced an electrophilicity index (w), as:
w ¼ l
2
2g
 
ð4Þ
It was proposed as a measure of the electrophilic power of a
molecule.
To expand the scope of cucurbituril and supramolecular
chemistry, we have investigated its energetic and geometric
properties with the means of DFT calculations. The DFT cal-
culations were performed at the B3PW91/LANL2DZ level of
theory.Au(1) 
) 
Cl(1) 
Cl(2) 
Au(1)
Br(1) 
Br(2) 
DT(Au)Cl2] and (b) [DMDT(Au)Br2].
Figure 4 Final optimized structures of (a) CB[5] and (b) CB[6].
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erly utilized in combination with each other, have proved toFigure 5 Geometrical structures of two orientations of pbe extremely powerful in solving the structural, energetic,
and dynamic problems associated with the CB[n] complexes.
In this research work, we have chosen Gold (III)-N,N-dim-
ethyldithiocarbamate ([DMDT(Au)X2] X = Cl, Br) complexes
as anticancer molecules as shown in Fig. 1. The goal of the
present study is to characterize, by accurate calculations, to
predict the inclusion complex formation of gold(III) anticancer
species with cucurbiturils (CB[n= 5,6]). We investigated the
stabilization energy, heat of formation of the complexes,
charge transfer, energies of the highest-occupied molecular
orbital (HOMO) and lowest-unoccupied molecular orbital
(LUMO) for the components and complexes as well as elec-
tronic properties and structural parameter i.e. bond lengths
was calculated for the different complexes.
2. Computational method
Computational analysis of host–guest inclusion complex for-
mation of the CB[n= 5, 6] with N,N-dimethyldithiocarba-
mate anticancer drugs was carried out, using the DFT
calculation at the level of B3PW91/LANL2DZ, and employ-
ing the G03 package (Frisch et al., 2003). The initial geome-
tries of anticancer drugs were optimized with DFT
calculations using the Berny analytical gradient algorithm.
Full geometry optimization of the CB[n] structures was per-
formed without geometrical or symmetry restrains. Harmonic
vibrational frequencies were computed for all structures. This
allowed us to estimate the zero-point vibrational energy
(ZPVE) correction for each structure, as well as to assess
the nature of the stationary points and therefore to character-
ize whether they are true minima on the respective potential
surfaces. The position of the guest molecules was determined
by the z coordinates of the anticancer drugs. The Z= 0 point
(center of the Cartesian coordinates) was chosen in the center
of the CB[n] cavity. The inclusion process was simulated by
placing the guest in one end of CB[n] cavity and then letting
it pass through the CB[n] cavity by steps. In every step, single
point calculations at the level of B3PW91/LANL2DZ were
used to obtain the heat of formation of the host–guest
complexes.
The electronic chemical potential (l) was calculated as half
of the energy of the Fermi level (EHOMO) plus the ﬁrst eigen-
value of the valence band (ELUMO), as follows:
l ¼ EHOMO þ ELUMOð Þ
2
ð5Þenetration of [DMDT(Au)X2] into the cavity of CB[n].
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nition of hardness (g) was obtained using a ﬁnite difference
approximation to the second derivative in Eq. (2), as (Pearson,
1988):
g ¼ ðI AÞ
2
ð6Þ
where I and A are the ionization potential and the electron
afﬁnity of the system, respectively. Eq. (6) could be further
approximated as follows, using Koopmans’ theorem (Chatt-
araj and Poddar, 1999):
g ¼ ðELUMO  EHOMOÞ
2
ð7Þ
Hard molecules thus have a large HOMO–LUMO gap and
soft molecules have a small one (Pearson, 1988).
3. Result and discussion
All initial geometries of drugs and CB[n] were optimized in the
framework of the density functional theory by use of the
B3PW91 functional. The optimized geometries of cucur-
bit[n]uril n= 5–7, are consistent with the earlier experimental
and modeling results (Bushchmann et al., 2006a, 2006b).
Figs. 3 and 4 show that the ﬁnal optimization geometries of
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Figure 6 Graphic diagrams of A orientation for emulation of the incl
[DMDT(Au)Cl2], (c) CB[6]-[DMDT(Au)Cl2], (d) CB[6]-[DMDT(Au)B
the Z-coordinate of the nitrogen atom in the alkyl amine group (the ZThe penetration of [DMDT(Au)X2] in the cavity of the
CB[n] can be done according to two orientations, A with the
amine group of the drug and B with the halogen atoms of
the drug (see Fig. 5). To determine the geometries of the
possible CB[n]/[DMDT(Au)Cl2] and CB[n]/[DMDT(Au)Br2]
complexes, [DMDT(Au)Cl2] and ([DMDT(Au)Br2] were
placed in one end of the CB[n] cavity and then letting it pass
through the CB[n] cavity which results indicate that the A ori-
entation of [DMDT(Au)X2] with CB[n] is signiﬁcantly more
favorable than that of B orientation.
The potential energy curve plots for the four different com-
plexes of CB[5] and CB[6] with [DMDT(Au)Cl2] and
[DMDT(Au)Br2] are shown in Fig. 6. Fig. 6 represents the
penetration of anticancer drugs into the cavity of CB[n] with
an amine group (A orientation). The structures of all com-
plexes at the minimum energy were fully optimized using
DFT calculations. The ﬁnal geometry optimization of CB[n]/
drugs show that the drugs were expelled from the cavity
(Fig. 7).
To understand the stability of the complexes, the binding
energy of CB[n]/[DMDT(Au)Cl2] and CB[n]/[DMDT(Au)Br2]
complexes at the B3PW91 level of theory was calculated.
The binding energy of complexes (DE) is obtained from the en-
ergy difference between the resulting complexes with the lowest
HF (heat of formation) energy and the energy of the isolated
cucurbit[n]urils and drugs as below:Z coordinate (Å)
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ee
)
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ee
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(b)
(d)
usion complex formation of (a) CB[5]-[DMDT(Au)Br2], (b) CB[5]-
r2] with DFT calculations. Position of the guest was determined by
= 0 point was chosen in the center of the CB[n] cavity).
Figure 7 Optimized structures at each energy minimum obtained from DFT calculations for the bird’s eye-view and the side view of (a)
CB[5]-[DMDT(Au)Br2], (b) CB[5]-[DMDT(Au)Cl2], (c) CB[6]-[DMDT(Au)Br2], (d) CB[6]-[DMDT(Au)Cl2] complexes.
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As can be seen in Table 1, the interaction between the
cucurbit molecules and the drug molecules is quite strong:
the binding energies of all complexes formed are about
87 kj/mol; which indicate that the inclusion complex process
is exothermic and the complex formed is more stable. Negative
interaction energies obtained from the DFT calculations showthe complexation of the guests into the CB[n] cavities is highly
favored. The effect of the cavity of CB[n] on the stability of the
complexation was considered. The ﬁt of the entire or at least a
part of the guest molecule in the CB[n] host cavity determines
the stability of the inclusion complex. The complexation
energies reported in Table 1 have a negative value which means
that the complexes formed are more stable than isolated
species.
Table 1 Thermodynamic parameters upon the inclusion complexation of CB[n= 5, 6] with [DMDT(Au)Cl2] and [DMDT(Au)Br2]
calculated by the DFT-based B3PW91/LANL2DZ method.
Compound Eb (kj/mol) DH(kj/mol) DG(kj/mol) DS(j/mol K)
[DMDT(Au)Cl2] – – – –
[DMDT(Au)Br2] – – – –
CB [5] – – – –
CB[6] – – – –
CB[5]/[DMDT(Au)Cl2] 86.788 81.390 35.1397 390.844
CB[5]/[DMDT(Au)Br2] 83.788 78.214 32.827 372.431
CB[6]/[DMDT(Au)Cl2] 88.327 82.745 21.558 349.834
CB[6]/[DMDT(Au)Br2] 90.269 80.122 19.384 333.746
Ebind is the binding energy of process.
DH is the enthalpy change of process.
DG is the Gibbs free energy change of process.
DS= (DHDG)/T is the entropy change of the process.
Table 2 The signiﬁcant bond lengths (A˚) and the calculated NBO charges (esu) of optimized drugs and complexes of
[(DMDT(Au)Cl2] with CB[n= 5,6]urils calculated by the B3PW91/LANL2DZ method.
[(DMDT(Au)Cl2] [(DMDT(Au)Cl2]/CB[5] [(DMDT(Au)Cl2]/CB[6]
Bond lengths (A˚)
Au(1)–Cl(1) 2.398 2.412 2.412
Au(1)–Cl(2) 2.398 2.412 2.415
Au(1)–S(1) 2.466 2.454 2.453
Au(1)–S(2) 2.467 2.454 2.452
N(1)–C(1) 1.332 1.317 1.316
N(1)–C(2) 1.475 1.480 1.479
N(1)–C(3) 1.478 1.482 1.483
C(1)–S(1) 1.789 1.799 1.800
C(1)–S(2) 1.789 1.800 1.799
C(2)–H(1) 1.091 1.094 1.093
C(3)–H(4) 1.092 1.093 1.093
Charge (esu)
Au(1) 0.32435 0.84762 0.82727
S(1) 0.07597 0.05436 0.05196
S(2) 0.08257 0.05978 0.03627
Cl(1) 0.29990 0.47456 0.48625
Cl(2) 0.29993 0.47538 0.48470
N(1) 0.41526 0.39265 0.38981
C(1) 0.04923 0.03635 0.03213
C(2) 0.42344 0.43104 0.42812
C(3) 0.43665 0.43330 0.43691
H(1) 0.24297 0.22959 0.22480
H(2) 0.23662 0.26516 0.26000
H(3) 0.23690 0.26389 0.26559
H(4) 0.24250 0.23590 0.25042
H(5) 0.24467 0.22712 0.25642
H(6) 0.23786 0.27384 0.25069
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CB[5]/[DMDT(Au)Br2] complexes (about 85.0 kj/mol) in the
inclusion process indicates that the cavity of CB[5] is good for
acceptance of the drugs as guest molecule in the cavity itself.
The key features in the complexation are summarized in
Table 1. With the change in the host molecule from CB[5] to
CB[6], the stability of the formed complexes is slightly in-
creased. In other words, the complex formed between CB[6]
and drugs is more stable than CB[5]/drugs. As a result, withthe increase in the size of the cavities of the CB[n], the stability
of the formed complexes is increased. Obtained data are in
agreement with the results of the inclusion complex formation
between CB[n] and oxaliplatin (Suvitha et al., 2010). Venkatar-
amanan et al. used a theoretical method based on ﬁrst princi-
ples which show that the formation energy increases with the
increase in the size of CB[n]. To investigate the thermodynamic
parameters of the inclusion processes the statistical thermody-
namic calculations were carried out at 1 atm and 298.15 K
Table 3 The signiﬁcant bond lengths (A˚) and the calculated NBO charges (esu) of optimized drugs and complexes of
[(DMDT(Au)Br2] with CB[n= 5,6]urils calculated by the B3PW91/LANL2DZ method.
[(DMDT(Au)Br2] [(DMDT(Au)Br2]/CB[5] [(DMDT(Au)Br2]/CB[6]
Bond lengths (A˚)
Au(1)–Br(1) 2.535 2.549 2.552
Au(1)–Br(2) 2.536 2.548 2.551
Au(1)–S(1) 2.483 2.469 2.465
Au(1)–S(2) 2.484 2.470 2.465
N(1)–C(1) 1.333 1.318 1.318
N(1)–C(2) 1.474 1.480 1.481
N(1)–C(3) 1.478 1.482 1.481
C(1)–S(1) 1.787 1.798 1.802
C(1)–S(2) 1.788 1.798 1.802
C(2)–H(1) 1.091 1.094 1.093
C(3)–H(4) 1.092 1.095 1.092
Charge (esu)
Au(1) 0.18055 0.16178 0.16255
S(1) 0.06489 0.06432 0.06176
S(2) 0.07046 0.05681 0.06170
Br(1) 0.21383 0.26236 0.27397
Br(2) 0.21216 0.26251 0.27396
N(1) 0.41707 0.38654 0.38544
C(1) 0.04941 0.02156 0.01627
C(2) 0.42377 0.43209 0.42917
C(3) 0.43738 0.43491 0.42926
H(1) 0.24327 0.22971 0.23075
H(2) 0.23558 0.27053 0.25951
H(3) 0.23560 0.26278 0.26252
H(4) 0.24321 0.23328 0.23083
H(5) 0.24335 0.22888 0.26251
H(6) 0.23671 0.27713 0.25961
Figure 8 The nearest intermolecular distances between hydrogen atom of drug with oxygen atom of CB[n]; (a) CB[6]/[DMDT(Au)Br2],
(b) CB[6]/[DMDT(Au)Cl2], (c) CB[5]/[DMDT(Au)Br2], (d) CB[5]/[DMDT(Au)Cl2].
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Table 4 HOMO, LUMO and Gap energy, chemical potential (l), hardness (g) and electrophilicity (x) of the drugs, CB[n]s and
inclusion complexes CB[n]/drugs.
Compound HOMO (eV) LUMO (eV) Gap (eV) l (eV) g (eV) x
DMDT(Au)Cl2 7.458 4.658 2.780 6.058 1.400 13.108
DMDT(Au)Br2 6.951 4.592 2.360 5.772 1.1796 14.118
CB[5] 6.657 0.389 7.046 3.134 3.523 1.394
CB[6] 6.230 1.123 7.354 2.554 3.677 0.887
CB[5]/DMDT(Au)Cl2 6.278 3.353 2.925 4.815 1.463 7.927
CB[5]/DMDT(Au)Br2 6.096 3.625 2.471 4.860 1.235 9.562
CB[6]/DMDT(Au)Cl2 6.4189 3.489 2.930 4.954 1.465 8.374
CB[6]/DMDT(Au)Br2 5.930 3.419 2.510 4.675 1.255 8.705
Figure 9 Typical counter plots of (a) HOMO and (b) LUMO for
the A orientations of the CB[6]-[DMDT(Au)Br2] complex.
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such as the Gibbs free energy changes (DG), the enthalpy
changes (DH), and the entropy changes of the process (DS)
were calculated. The results, summarized in Table 1, show that
the values of Gibbs free energy changes (DG) for all structures
are positive, which imply that they do not occur spontaneously
at room temperature. On the other hand, the obtained values
for enthalpy changes (DH) for all complexes are negative,
which means that the processes are exothermic.
We now turn to a discussion of the structural parameters of
their complexes. The structural parameters calculated by the
B3PW91 method of the isolated CB[5] and CB[6] and of their
complexes with [DMDT(Au)Cl2] and [DMDT(Au)Br2] are
presented in Tables 2 and 3. These results indicate that there
are no signiﬁcant changes in bond lengths; this is mainly ob-
served for the bonding involving the nitrogen atom during
the inclusion processes. The nearest intermolecular distance
between CB[n] and drugs to investigate the hydrogen bonds
was considered. The ﬁnal optimization structures of complexes
(Fig. 8) show that the nearest distance was found between the
oxygen atom of carbonyl portal groups of CB[n] and H atoms
of amine group of drugs. In these cases, the anticancer drugs
are embedded in the CB[n] cavity, which is consistent with
the structures suggested by NMR spectroscopy (Oh et al.,
2001). The amine nitrogen atom of drug essentially lie on the
plane made by ﬁve and six oxygen atoms of CB[5] and CB[6]
portal while forming hydrogen bonds with the oxygen atom.
From Fig. 8, we ﬁnd that the six oxygen atoms of CB[6] form
strong interactions with ﬁve hydrogen (C‚O–H= 2.607 A˚)
and the nearest distance between H atom of [DMDT(Au)Br2]
and O atom of CB[6] in CB[6]/[DMDT(Au)Br2] complex is ob-
tained as about 2.602 A˚. Also, the hydrogen intermolecular
interactions for CB[6]/[DMDT(Au)Cl2] complex are consid-
ered. When the guest molecule changed from [DMDT(Au)Br2]
to [DMDT(Au)Cl2], the average intermolecular distance chan-
ged to 2.487 A˚ (C‚O–H= 2.487 A˚). In addition, four hydro-
gen bonds were found for the CB[6]/[DMDT(Au)Cl2] complex
from Fig. 8, which means that the CB[6]/[DMDT(Au)Br2]
complex is slightly more stable than CB[6]/[DMDT(Au)Cl2].
These results are in well agreement with the results of the sta-
bilization energy. As a result, the synergetic effects of the
hydrogen bonding appear to be the major factor for the stabil-
ity of the complexes.
If the host molecule from CB[6] changed to CB[5], the near-
est intermolecular distances and the numbers of hydrogen
bonding changed. For the CB[5]/[DMDT(Au)Cl2] complex,
ﬁve glycol-uril carbonyl groups form ﬁve hydrogen bonding
with ﬁve hydrogen atoms of [DMDT(Au)Cl2] with the nearestintermolecular distance about 2.491 A˚ while the CB[5]/
[DMDT(Au)Br2] complex forms just four hydrogen bonding
with (C‚O–H= 2.469 A˚) which means that the CB[5]/
[DMDT(Au)Cl2] complex is slightly more stable than CB[5]/
[DMDT(Au)Br2] (see Fig. 8).
One of the essential characteristics affecting the possibility
of interaction of the host–guest complexes inside the cavity is
the distribution of effective charges on the atoms. Tables 2
and 3 indicate that the partial charge of the Au, Cl, Br, N
and H atoms of drugs signiﬁcantly changed during the com-
plexation. Charge distribution computed by the natural bond
434 Z. Mahdavifar, S. Samieeorbital (NBO) approach reveals that the charges of the Cl(1),
Cl(2), Br(1) and Br(2) atoms of [DMDT(Au)Br2] and
[DMDT(Au)Cl2] in the complexes are more negative than
those in the isolated components while the H atoms are more
positive than those in the isolated drugs. This means that when
the guest molecule interacts with CB[n], its charge distribution
changes. So, when [DMDT(Au)Br2] and [DMDT(Au)Cl2]
molecules penetrate into the CB[n] cavities by alkyl groups,
there is a charge-transfer from drugs to CB[n] producing a
common chemical potential so, that strong hydrogen bonding
occur. The atomic numbering schemes of drugs are shown in
Fig. 3.
The results of the HOMO and LUMO energies of the com-
plexes are summarized in Table 4. The most important terms in
this kind of interaction are contributed from the partial charge
transfer between the HOMO of one component and the
LUMO of another. The HOMO–LUMO (H–L) energy gap
for these complexes is 2.5–3.0 eV. According to the difference
between the frontier orbital energies when the energy gap is
higher, the system behaves like a very stable molecule. In addi-
tion, the high HOMO energy indicates that the molecule can
undergo an electrophilic attack with a large probability. These
results indicate that the HOMO orbital is localized on the
drugs and the LUMO orbital is observed on the CB[n]. The
typical counter plots of HOMO and LUMO of CB[6]/
[DMMT(Au)Br2 are shown in Fig. 9.
The global indices of reactivity in the context of DFT are
presented in Table 4. The value of electronic chemical poten-
tial, hardness and electrophilicity for complexes are differing
from the individual CB[n] and drug molecules. When drug
molecule and CB[n] are brought together, electrons will ﬂow
from lower electronegativity (v) to that of higher v. On the
other hand, electrons are transferred to the lower electronic
chemical potential, until the electronic chemical potentials be-
come equal (Pearson, 1988). The difference in electronegativity
drives the electron transfer, and the sum of the hardness
parameters acts as a resistance. As a result, the electrons will
ﬂow from a deﬁnite occupied orbital in drugs and will go into
a deﬁnite empty orbital in CB[n]. Also, results indicate that
when the drug molecules penetrate into the cavity of the
CB[n], the hardness of the complexes decreased, which
means that the stability of the complexes is lower than pristine
CB[n].
4. Conclusion
The purpose of this research work is an attempt to explain the
inclusion complex formation of [DMDT(Au)Cl2] and
[DMDT(Au)Br2] with cucurbit [n= 5, 6] urils using DFT cal-
culation. We took into account only the stoichiometry 1:1. To
summarize, the following conclusion can be made. Molecular
modeling calculations, predict that [DMDT(Au)X2] was ex-
pelled from the cavity of CB[n= 5,6]. The analyses of the ther-
modynamic calculations indicate that the enthalpy
contribution is favorable to the complex formation. Results
of the binding energy show that the CB[6]/[DMDT(Au)Br2]
complex is more stable than others. The ﬁnal optimization
geometries show that the hydrogen bonding between the portal
oxygen atom of CB[n] and the hydrogen atom of amine group
of drugs and electrostatic interactions are the major factors
contributing to the overall stabilities of the complexations.References
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